Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN)‘s stock had its “outperform” rating reiterated by equities researchers at Leerink Swann in a research note issued to investors on Monday.

Several other brokerages have also issued reports on ALXN. Royal Bank of Canada set a $188.00 target price on Alexion Pharmaceuticals and gave the company a “buy” rating in a research report on Monday, December 12th. Wedbush reaffirmed a “neutral” rating and set a $135.00 target price on shares of Alexion Pharmaceuticals in a research report on Tuesday, December 13th. JPMorgan Chase & Co. set a $170.00 target price on Alexion Pharmaceuticals and gave the company a “buy” rating in a research report on Tuesday, February 7th. Barclays PLC raised Alexion Pharmaceuticals from an “equal weight” rating to an “overweight” rating and raised their target price for the company from $150.00 to $155.00 in a research report on Tuesday, November 29th. Finally, BMO Capital Markets reaffirmed an “outperform” rating on shares of Alexion Pharmaceuticals in a research report on Thursday, January 12th. Seven investment analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $167.74.

Analyst Recommendations for Alexion Pharmaceuticals (NASDAQ:ALXN)

Shares of Alexion Pharmaceuticals (NASDAQ:ALXN) traded down 1.74% during midday trading on Monday, hitting $119.96. 1,029,091 shares of the stock were exchanged. Alexion Pharmaceuticals has a 1-year low of $109.12 and a 1-year high of $162.00. The stock’s 50-day moving average price is $128.71 and its 200-day moving average price is $126.30. The firm has a market capitalization of $26.94 billion, a price-to-earnings ratio of 68.16 and a beta of 1.39.

Alexion Pharmaceuticals (NASDAQ:ALXN) last released its quarterly earnings results on Thursday, February 16th. The biopharmaceutical company reported $1.26 EPS for the quarter, beating analysts’ consensus estimates of $1.25 by $0.01. The business earned $831 million during the quarter, compared to analyst estimates of $840.69 million. Alexion Pharmaceuticals had a return on equity of 10.58% and a net margin of 12.46%. Alexion Pharmaceuticals’s quarterly revenue was up 18.5% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.13 EPS. On average, analysts forecast that Alexion Pharmaceuticals will post $5.25 EPS for the current year.

Your IP Address:

In other Alexion Pharmaceuticals news, EVP John B. Moriarty sold 3,538 shares of the firm’s stock in a transaction dated Tuesday, February 7th. The stock was sold at an average price of $125.79, for a total value of $445,045.02. Following the completion of the transaction, the executive vice president now owns 46,801 shares in the company, valued at approximately $5,887,097.79. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, SVP Heidi L. Wagner sold 1,932 shares of the firm’s stock in a transaction dated Tuesday, February 7th. The stock was sold at an average price of $125.97, for a total value of $243,374.04. Following the completion of the transaction, the senior vice president now owns 30,241 shares of the company’s stock, valued at approximately $3,809,458.77. The disclosure for this sale can be found here. In the last 90 days, insiders sold 88,908 shares of company stock valued at $12,042,066. 4.41% of the stock is owned by corporate insiders.

Several hedge funds have recently modified their holdings of the stock. Cornerstone Advisors Inc. increased its stake in shares of Alexion Pharmaceuticals by 47.4% in the third quarter. Cornerstone Advisors Inc. now owns 964 shares of the biopharmaceutical company’s stock worth $118,000 after buying an additional 310 shares during the period. Deltec Asset Management LLC acquired a new stake in shares of Alexion Pharmaceuticals during the third quarter worth about $1,495,000. MAI Capital Management increased its stake in shares of Alexion Pharmaceuticals by 21.5% in the third quarter. MAI Capital Management now owns 5,201 shares of the biopharmaceutical company’s stock worth $637,000 after buying an additional 920 shares during the period. National Pension Service increased its stake in shares of Alexion Pharmaceuticals by 8.7% in the third quarter. National Pension Service now owns 154,603 shares of the biopharmaceutical company’s stock worth $18,945,000 after buying an additional 12,438 shares during the period. Finally, Parametrica Management Ltd acquired a new stake in shares of Alexion Pharmaceuticals during the third quarter worth about $232,000. Hedge funds and other institutional investors own 94.98% of the company’s stock.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

5 Day Chart for NASDAQ:ALXN

Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.